LOS ANGELES, Feb. 6, 2017 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
Chairman and CEO Steven A. Kriegsman
and David Haen, Vice President of
Business Development and Investor Relations, will present a
corporate update at the 19th Annual BIO CEO &
Investor Conference on Monday, February
13th at 4:00 p.m. Eastern
Time at the Waldorf Astoria Hotel in New York City.
Based on positive, statistically significant results from
CytRx's pivotal Phase 3 trial evaluating aldoxorubicin compared to
investigator's choice in patients with previously treated relapsed
or refractory sarcomas, CytRx is scheduled to meet with the FDA
this quarter to discuss the regulatory path for a New Drug
Application (NDA).
A live and archived webcast of the presentation will be
available at
http://www.veracast.com/webcasts/bio/ceoinvestor2017/42130220022.cfm.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and
development company specializing in oncology. CytRx currently is
focused on the clinical development of aldoxorubicin, its improved
version of the widely used chemotherapeutic agent
doxorubicin. CytRx is also expanding its pipeline of oncology
candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated
Drug Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker technology
for the development of a new class of anti-cancer therapies.
About the BIO CEO & Investor Conference
Now in its 19th year, the BIO CEO & Investor Conference is
one of the largest investor conferences focused on established and
emerging publicly traded and select private biotech
companies. The conference provides a neutral forum where
institutional investors, industry analysts, and senior
biotechnology executives have the opportunity to shape the future
investment landscape of the biotechnology industry.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended. Such statements involve risks and uncertainties that
could cause actual events or results to differ materially from the
events or results described in the forward-looking statements,
including risks relating to the outcome, timing and results of
CytRx's clinical testing of aldoxorubicin and preclinical testing
of its LADR™ linker technology platform, the outcome, timing or
results of CytRx's clinical testing of aldoxorubicin, the risk that
any future pre-clinical or human testing of compounds based on the
LADR™ technology platform might not show efficacy or reduced side
effects of those compounds, risks related to CytRx's ability to
manufacture its drug candidates in a timely fashion,
cost-effectively or in commercial quantities in compliance with
stringent regulatory requirements, risks related to CytRx's need
for additional capital or strategic partnerships to fund its
ongoing working capital needs and development efforts, including
the Phase 2 and Phase 3 clinical development of aldoxorubicin for
SCLC and STS, respectively, and the preclinical and clinical
development of compounds based on the LADR™ technology platform,
risks related to lawsuits that have been brought against the
Company and its officers and/or directors for alleged violations of
the securities laws, and the risks and uncertainties described in
the most recent annual and quarterly reports filed by CytRx with
the Securities and Exchange Commission and current reports filed
since the date of CytRx's most recent annual report. All
forward-looking statements are based upon information available to
CytRx on the date the statements are first published. CytRx
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Company Contact:
CytRx Corporation
David J. Haen
Vice President, Business Development and Investor
Relations
(310) 826-5648, ext 304
dhaen@cytrx.com
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytrx-to-present-at-the-19th-annual-bio-ceo--investor-conference-300402309.html
SOURCE CytRx Corporation